EPISODE · Jun 27, 2025 · 12 MIN
Breakthroughs in Targeted Therapy for Lung Cancer: What Every Patient Should Know
In this episode, we explore the latest advancements in targeted therapy for lung cancer and what they mean for patients today. Learn how personalized treatments based on genetic testing are changing the way doctors treat non-small cell lung cancer (NSCLC) and why these therapies offer new hope.You’ll learn:What targeted therapy is and how it differs from traditional chemotherapyHow EGFR, ALK, and ROS1 mutations guide treatment choicesWhy genetic testing is essential for personalized cancer careThe benefits of fewer side effects and better quality of lifeHow ongoing clinical trials are shaping the future of lung cancer treatmentWhat questions to ask your doctor about genetic testing and targeted optionsWhether you're newly diagnosed or exploring advanced treatment paths, this episode offers clear, practical insights to help you understand your options.Blog Link: Advancements in Targeted Therapy for Lung CancerSend us Fan MailThank you for listening to The Onco Life Podcast, your trusted source for expert cancer information and patient-centered education.Author: Dr. CHRISTINA NG VAN TZE📍 Visit us at oncolifecentre.com 📞 Call: +603-2242-2620 📧 Book a consultation or ask a question — we're here to support your journey.
What this episode covers
In this episode, we explore the latest advancements in targeted therapy for lung cancer and what they mean for patients today. Learn how personalized treatments based on genetic testing are changing the way doctors treat non-small cell lung cancer (NSCLC) and why these therapies offer new hope. You’ll learn: What targeted therapy is and how it differs from traditional chemotherapyHow EGFR, ALK, and ROS1 mutations guide treatment choicesWhy genetic testing is essential for personalized cancer ...
NOW PLAYING
Breakthroughs in Targeted Therapy for Lung Cancer: What Every Patient Should Know
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m